Yervoy (ipilimumab) / BMS 
Welcome,         Profile    Billing    Logout  
 197 Diseases   398 Trials   398 Trials   21826 News 


12345678910111213...266267»
  • ||||||||||  Yervoy (ipilimumab) / BMS
    Review, Journal, Checkpoint inhibition:  Beyond checkpoint inhibitors: the three generations of immunotherapy. (Pubmed Central) -  Jan 31, 2025   
    Following the approval of the first checkpoint inhibitor ipilimumab against CTLA-4 in melanoma in 2011, there has been a rapid development of tumor immunotherapy...In order to better understand the mechanism of action of all major classes of immunotherapy, design clinical trials taking advantage of different types of immunotherapeutic agents and use them rationally in clinical practice either in combination or in sequence, we propose the group all immunotherapies into three generations: with CTLA-4, PD-1 and PD-L1 inhibitors as the first generation, agents that target the checkpoint modulators as the second generation, while those that target TME as the third generation. This review discusses all three generations of immunotherapy in oncology, their mechanism of actions, major clinical trial results and indication, strategies for future clinical trial designs and rational clinical applications.
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
    Clinical data, Journal, Checkpoint inhibition:  Immune checkpoint inhibitor infusion times and clinical outcomes in patients with melanoma. (Pubmed Central) -  Jan 31, 2025   
    Given the rarity and poor prognosis of primary malignant melanoma of the esophagus, this case provides valuable insights for treatment strategies. Late immunotherapy infusion times were associated with inferior outcomes when considering all infusions, but not when considering initial (first 4) infusions.
  • ||||||||||  Bavencio (avelumab) / EMD Serono, Yervoy (ipilimumab) / BMS
    Review, Journal, PD(L)-1 Biomarker, IO biomarker:  Pathology and molecular pathology of carcinoma of the penis (Pubmed Central) -  Jan 30, 2025   
    Late immunotherapy infusion times were associated with inferior outcomes when considering all infusions, but not when considering initial (first 4) infusions. Neither microsatellite instability nor mismatch-repair deficiency appear to play a
  • ||||||||||  Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
    Trial completion date:  Window Study of Nivolumab With or Without Ipilimumab in Squamous Cell Carcinoma of the Oral Cavity (clinicaltrials.gov) -  Jan 29, 2025   
    P2,  N=30, Active, not recruiting, 
    Nivolumab/ipilimumab did not improve disease-free survival compared with chemotherapy in patients with ypN+ and/or R1 gastro-oesophageal adenocarcinoma following neoadjuvant chemotherapy and surgery. Trial completion date: Dec 2024 --> Dec 2025
  • ||||||||||  Review, Journal:  Synergistic Interactions Between Probiotics and Anticancer Drugs: Mechanisms, Benefits, and Challenges. (Pubmed Central) -  Jan 28, 2025   
    These findings highlight insights for considering specific strains and engineered probiotic applications, preferred doses and timing of treatment, and personalized therapies to enhance the efficacy of cancer therapy. Accordingly, targeted interventions and guidelines establishment needs extensive randomized controlled trials as probiotic-based cancer therapy has not been approved by Food and Drug Administration (FDA).
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
    Review, Journal:  Exploring the progress and trends of immunotherapy for type 1 diabetes: A comprehensive bibliometric analysis spanning nearly two decades. (Pubmed Central) -  Jan 28, 2025   
    Accordingly, targeted interventions and guidelines establishment needs extensive randomized controlled trials as probiotic-based cancer therapy has not been approved by Food and Drug Administration (FDA). The outcomes of the study are instrumental in enabling scholars to comprehend the evolving trajectory of immunotherapeutic approaches for T1D and facilitate the swift recognition of emerging research pathways.
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
    Review, Journal, Checkpoint inhibition:  Immune checkpoint inhibitors in pediatric patients with melanoma: a systematic literature review. (Pubmed Central) -  Jan 27, 2025   
    Despite scarce, heterogenous data, this review can be a reference for clinicians. Future clinical trials should include adolescents to grow the evidence base on immune checkpoint inhibitors in pediatric melanoma.
  • ||||||||||  Actemra IV (tocilizumab) / Roche, JW Pharma, Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
    Journal:  Hemophagocytic Lymphohistiocytosis (HLH) Following Immune Checkpoint Therapy (ICT). (Pubmed Central) -  Jan 16, 2025   
    The diagnosis of HLH is a challenge due to nonspecific symptoms and overlap with other systemic conditions, which can lead to delays in receiving appropriate treatment and potentially poor patient outcomes. This case illustrates the management of HLH caused by nivolumab plus ipilimumab combination therapy through the use of corticosteroids and tocilizumab in a patient with metastatic clear cell renal cell carcinoma.
  • ||||||||||  Review, Journal:  Topical and Intralesional Treatments for Skin Metastases and Locoregionally Advanced Melanoma. (Pubmed Central) -  Jan 12, 2025   
    Brief comments on other alternatives in development such as interferon-alpha, interleukin-12, ipilimumab and intralesional daromun are presented...It has also been described in a few papers that non-injected lesions may respond after the application of a local therapy in distant skin-metastases. Many of these intralesional treatments are being combined in different investigations with systemic immunotherapies, with the aim of obtaining synergic responses in those patients with refractory disease.
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
    Journal, PD(L)-1 Biomarker, IO biomarker:  Outcomes of Immunotherapy Treatment in Sinonasal Mucosal Melanoma. (Pubmed Central) -  Jan 12, 2025   
    Approximately half of patients will have a local response following immunotherapy, but it is rare to have improvement at metastatic locations. Further research within our group will assess optimal timing and markers that are predictive of response.
  • ||||||||||  Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
    Retrospective data, Journal, Checkpoint inhibition:  Incidence and risk factors of immune checkpoint inhibitor-induced colitis in Korean patients with cancer. (Pubmed Central) -  Jan 12, 2025   
    ICI-induced colitis had an incidence rate of 3.5% and was associated with the combination of nivolumab and ipilimumab. Most patients with ICI-induced colitis developed mild symptoms that improved with supportive care alone, making ICI therapy resumption possible.
  • ||||||||||  Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
    Journal, PD(L)-1 Biomarker:  Neoadjuvant Nivolumab Plus Ipilimumab Versus Chemotherapy in Resectable Lung Cancer. (Pubmed Central) -  Jan 12, 2025   
    Most patients with ICI-induced colitis developed mild symptoms that improved with supportive care alone, making ICI therapy resumption possible. Neoadjuvant nivolumab plus ipilimumab showed potential long-term clinical benefit versus chemotherapy, despite early crossing of EFS curves in the preoperative phase and a lower rate of high-grade toxicity.
  • ||||||||||  Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
    Trial completion date, Trial primary completion date:  Recombinant Interleukin-15 in Combination With Checkpoint Inhibitors Nivolumab and Ipilimumab in People With Refractory Cancers (clinicaltrials.gov) -  Jan 10, 2025   
    P1,  N=50, Recruiting, 
    Nivolumab plus ipilimumab with or without chemotherapy provides a long-term, durable clinical benefit in patients with metastatic NSCLC and tumor PD-L1 lower than 1%, supporting the use of this strategy as a first-line treatment option in this population with high unmet need. Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Dec 2024 --> Dec 2025
  • ||||||||||  Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
    Retrospective data, Review, Journal, Combination therapy:  Is nivolumab alone or in combination with ipilimumab more effective for treating lung cancer? a meta-analysis. (Pubmed Central) -  Jan 9, 2025   
    Although combination treatment significantly improved progression-free survival in NSCLC patients, it was also associated with a greater risk of adverse events and treatment-related mortality than nivolumab monotherapy. The current evidence is insufficient for choosing combination treatment over nivolumab monotherapy.